Synopsis
0
EU WC
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Aldomet
2. Alpha Methyl L Dopa
3. Alpha Methyldopa
4. Alpha-methyl-l-dopa
5. Alpha-methyldopa
6. Alphamethyldopa
7. Apo Methyldopa
8. Apo-methyldopa
9. Dopamet
10. Dopegit
11. Dopegyt
12. Dopergit
13. Hydopa
14. Meldopa
15. Methyldopate
16. Nu Medopa
17. Nu-medopa
18. Sembrina
1. 555-30-6
2. Alphamethyldopa
3. Alpha Medopa
4. Methyl Dopa
5. Methyldopa Anhydrous
6. Aldomet
7. Baypresol
8. L-alpha-methyldopa
9. Dopamet
10. Alpha-methyl Dopa
11. Hyperpax
12. Presolisin
13. Sedometil
14. Medomet
15. Alpha-methyldopa
16. Dopegyt
17. Methyl-l-dopa
18. L-(-)-alpha-methyldopa
19. L-methyl Dopa
20. Methyldopum
21. Metildopa
22. Medopren
23. Presinol
24. (s)-(-)-alpha-methyldopa
25. 3-(3,4-dihydroxyphenyl)-2-methyl-l-alanine
26. L-(alpha-md)
27. 3-hydroxy-alpha-methyl-l-tyrosine
28. L-alpha-methyl Dopa
29. Sembrina
30. Alpha-methyl-l-dopa
31. Dopamethyperpax
32. Aldometil
33. Grospisk
34. Methoplain
35. Becanta
36. Dopatec
37. Hypolag
38. Medopa
39. Medopal
40. Alpha-methyldopa (van)
41. Aldoril
42. Alpha-methyldihydroxyphenylalanine
43. L-3-(3,4-dihydroxyphenyl)-2-methylalanine
44. (s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic Acid
45. Alpha-methyl-l-3,4-dihydroxyphenylalanine
46. L-alpha-methyl-3,4-dihydroxyphenylalanine
47. L-methyldopa
48. (-)-methyldopa
49. Anhydrous Methyldopa
50. Methyldopa [inn]
51. (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic Acid
52. Aldoril D30
53. Aldoril D50
54. Methyldopa (l,-)
55. Bayer 1440 L
56. Levo-3-(3,4-dihydroxyphenyl)-2-methylalanine
57. Amd
58. C10h13no4
59. Methyldopa (levorotatory)
60. L-(-)-3-(3,4-dihydroxyphenyl)-2-methylalanine
61. Alpha-methyl-beta-(3,4-dihydroxyphenyl)-l-alanine
62. L(-)-beta-(3,4-dihydroxyphenyl)-alpha-methylalanine
63. L-(-)-alpha-methyl-beta-(3,4-dihydroxyphenyl)alanine
64. Methyldopa (inn)
65. L-2-amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic Acid
66. Methyldopa, Anhydrous
67. Mk-351;methyldopa
68. Chebi:61058
69. Aldomet (tn)
70. Dopegit
71. (-)-.alpha.-methyldopa
72. Methyldopa Sesquihydrate
73. 41372-08-1
74. Lederdopa
75. Bayer-1440l
76. Mls000028644
77. M4r0h12f6m
78. Mk-351
79. Apo-methyldopa
80. Nu-medopa
81. Nsc-169916
82. Nsc-760080
83. J9.247i
84. L-.alpha.-methyldopa
85. Methyldopa Hydrate
86. Novomedopa
87. Smr000059170
88. .alpha.-methyl-l-dopa
89. L-tyrosine, 3-hydroxy-.alpha.-methyl-
90. Methyldopum [inn-latin]
91. Metildopa [inn-spanish]
92. (s)-(-)-.alpha.-methyldopa
93. Methyldopa (anhydrous)
94. 3-hydroxy-.alpha.-methyl-l-tyrosine
95. L-tyrosine, 3-hydroxy-alpha-methyl-
96. 27289-76-5
97. Ccris 4671
98. Hsdb 218
99. Sr-01000597712
100. Einecs 209-089-2
101. Nsc 169916
102. Unii-m4r0h12f6m
103. Medoba
104. L-a-methyldopa
105. A-methyl Dopa
106. Nsc169916
107. Tyrosine, 3-hydroxy-.alpha.-methyl-
108. A-methyl-l-dopa
109. 3,4-dihydroxy-2-methylphenylalanine #
110. Cas-555-30-6
111. Prestwick_732
112. (-)-a-methyldopa
113. A-methyldopa (van)
114. .alpha.-methyl-l-3,4-dihydroxyphenylalanine
115. Methyldopa (aldomet)
116. 88620-56-8
117. Alanine, 3-(3,4-dihydroxyphenyl)-2-methyl-, L-(-)-
118. Methyldopa 250 Tab
119. (-)-alpha-methyldopa
120. L-(-)--methyldopa
121. L(-)-a-methylalanine
122. L-(-)-a-methyldopa
123. Spectrum_000937
124. Tocris-0584
125. Mk-351; Methyldopa
126. Methyldopa [mi]
127. Nu-medopa Tab 125mg
128. Nu-medopa Tab 250mg
129. Nu-medopa Tab 500mg
130. L-(-)-?-methyldopa
131. (-)-3-(3,4-dihydroxyphenyl)-2-methyl-l-alanine Sesqui-hydrate
132. Novo-medopa Tab 125mg
133. Novo-medopa Tab 250mg
134. Novo-medopa Tab 500mg
135. Prestwick0_000326
136. Prestwick1_000326
137. Prestwick2_000326
138. Prestwick3_000326
139. Spectrum2_001068
140. Spectrum3_000501
141. Spectrum4_000054
142. Spectrum5_001295
143. Methyldopa [hsdb]
144. (s)-(-)-a-methyldopa
145. L(-)-alpha-methylalanine
146. Dsstox_cid_3295
147. Chembl459
148. Epitope Id:146097
149. L-(-)- Alpha-methyldopa
150. Apo Methyldopa Tab 125mg
151. Apo Methyldopa Tab 250mg
152. Apo Methyldopa Tab 500mg
153. Dsstox_rid_76962
154. Methyldopa [who-dd]
155. Dsstox_gsid_23295
156. L-(-)- Alpha -methyldopa
157. L-(a-md)
158. Lopac0_000853
159. Schembl34003
160. Bspbio_000331
161. Bspbio_002021
162. Kbiogr_000547
163. Kbioss_001417
164. Cid_38853
165. Mls006011978
166. Bidd:gt0620
167. Divk1c_000142
168. Methyldopa 125 Tab 125mg
169. Methyldopa 500 Tab 500mg
170. Spectrum1500403
171. Spbio_001056
172. Spbio_002252
173. Bpbio1_000365
174. Gtpl5217
175. Dtxsid5023295
176. Bdbm48449
177. Hms500h04
178. Kbio1_000142
179. Kbio2_001417
180. Kbio2_003985
181. Kbio2_006553
182. Kbio3_001521
183. Zinc20255
184. 3-(3,4-dihydroxyphenyl)-2-methyl-l-alanine Sesquihydrate
185. 5-amino-2-fluorophenylboronicacid
186. Ninds_000142
187. Hms1569a13
188. Hms1920n09
189. Hms2090b11
190. Hms2091f04
191. Hms2096a13
192. Hms2235n11
193. Hms3262l07
194. Hms3372j14
195. Hms3411g18
196. Hms3675g18
197. Hms3713a13
198. Hms3887i15
199. Mk-35
200. Pharmakon1600-01500403
201. L-(-)-a-methyl-a-methyl-aldomin
202. Hy-b0225
203. Tox21_202610
204. Tox21_500853
205. Anhydrous Methyldopa [mart.]
206. Ccg-40120
207. Dl-443
208. Mfcd00004186
209. Nsc760080
210. S1642
211. A-methyl-l-3,4-dihydroxyphenylalanine
212. Akos015960582
213. Ac-8431
214. Db00968
215. Ks-1424
216. Lp00853
217. Sdccgsbi-0050829.p002
218. Idi1_000142
219. Ncgc00024667-01
220. Ncgc00024667-02
221. Ncgc00024667-03
222. Ncgc00024667-05
223. Ncgc00024667-06
224. Ncgc00024667-07
225. Ncgc00024667-08
226. Ncgc00024667-09
227. Ncgc00024667-10
228. Ncgc00024667-11
229. Ncgc00024667-13
230. Ncgc00024667-21
231. Ncgc00260158-01
232. Ncgc00261538-01
233. Ac-11671
234. As-13052
235. L-(-)-alpha-methyl-alpha-methyl-aldomin
236. Carbidopa Impurity A [ep Impurity]
237. L-a-methyl-(3, 4-dihydroxyphenyl)alanine
238. D1817
239. Eu-0100853
240. 3-(3,4-dihydroxyphenyl)-?-methyl-l-alanine
241. L-alpha-methyl-(3, 4-dihydroxyphenyl)alanine
242. C07194
243. D08205
244. D82313
245. Ab00052043_09
246. Ab01275508-01
247. Ab01275508_02
248. 3-(3,4-dihydroxyphenyl)-alpha-methyl-l-a Lanine
249. L-tyrosine, 3-hydroxy-alpha-methyl-, Homopolymer
250. Q412621
251. L-(-)-3-(3,4-dihydroxyphenyl)-2-methyl-alanine
252. Q-201392
253. Sr-01000597712-1
254. Sr-01000597712-3
255. W-105555
256. 3,4-dihydroxy-2-methylphenylalanine (acd/name 4.0)
257. (-)-.alpha.-methyl-3,4-dihydroxyphenylalanine
258. L-.alpha.-methyl-3-(3,4)-dihydroxyphenylalanine
259. Z1565440340
260. (s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoicacid
261. Methyldopa, European Pharmacopoeia (ep) Reference Standard
262. (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methyl-propanoic Acid
263. (2s)-2-azaniumyl-3-(3,4-dihydroxyphenyl)-2-methylpropanoate
264. Methyldopa, United States Pharmacopeia (usp) Reference Standard
265. 3-(3,4-dihydroxyphenyl)-2-methyl-l-alanine (h-l-ametyr(3-oh)-oh)
266. Methyldopa For System Suitability, European Pharmacopoeia (ep) Reference Standard
267. L-(-)-afae'a Centa' Nota Inverted Exclamation Markafasa'a
268. Afae'adaggeratrade Mark?-methyldopa
| Molecular Weight | 211.21 g/mol |
|---|---|
| Molecular Formula | C10H13NO4 |
| XLogP3 | -1.9 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 3 |
| Exact Mass | 211.08445790 g/mol |
| Monoisotopic Mass | 211.08445790 g/mol |
| Topological Polar Surface Area | 104 Ų |
| Heavy Atom Count | 15 |
| Formal Charge | 0 |
| Complexity | 246 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Methyldopa |
| PubMed Health | Methyldopa (By mouth) |
| Drug Classes | Antihypertensive, Cardiovascular Agent |
| Drug Label | Methyldopa is an antihypertensive and is the L-isomer of alpha-methyldopa. It is levo-3-(3,4-dihydroxyphenyl)-2-methylalanine sesquihydrate. Methyldopa is supplied as tablets for oral administration, containing 125 mg, 250 mg and 500 mg of methyldopa... |
| Active Ingredient | Methyldopa |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 250mg; 500mg |
| Market Status | Prescription |
| Company | Accord Hlthcare; Watson Labs; Ivax Sub Teva Pharms; Mylan |
| 2 of 2 | |
|---|---|
| Drug Name | Methyldopa |
| PubMed Health | Methyldopa (By mouth) |
| Drug Classes | Antihypertensive, Cardiovascular Agent |
| Drug Label | Methyldopa is an antihypertensive and is the L-isomer of alpha-methyldopa. It is levo-3-(3,4-dihydroxyphenyl)-2-methylalanine sesquihydrate. Methyldopa is supplied as tablets for oral administration, containing 125 mg, 250 mg and 500 mg of methyldopa... |
| Active Ingredient | Methyldopa |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 250mg; 500mg |
| Market Status | Prescription |
| Company | Accord Hlthcare; Watson Labs; Ivax Sub Teva Pharms; Mylan |
Adrenergic alpha-Agonists; Antihypertensive Agents; Sympatholytics
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
Methyldopa is indicated in the treatment of moderate to severe hypertension, including that complicated by renal disease. /Included in US product labeling/
USP Convention. USPDI - Drug Information for the Health Care Professional. 17th ed. Volume I. Rockville, MD: Convention, Inc., 1997. (Plus Updates)., p. 2000
Methyldopa is an effective antihypertensive agent when given in conjunction with a diuretic.
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 788
THE USUAL INITIAL DOSE OF METHYLDOPA IS 250 MG TWICE DAILY, AND THERE APPEARS TO BE LITTLE ADDNL EFFECT WITH DOSES OVER 2 G.
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 788
For more Therapeutic Uses (Complete) data for METHYLDOPA (6 total), please visit the HSDB record page.
Methyldopa should be used with caution in patients with a history of previous liver disease or dysfunction and is not recommended for use in patients with pheochromocytoma. Methyldopa is contraindicated in patients with active hepatic disease, such as acute hepatitis and active cirrhosis, and in patients in whom previous methyldopa therapy was associated with liver abnormalities or direct Coombs' positive hemolytic anemia. Methyldopa is contraindicated in patients receiving monoamine oxidase (MAO) inhibitors.
McEvoy, G.K. (ed.). American Hospital Formulary Service-Drug Information 19 98. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1998 (Plus Supplements)., p. 1512
Patients who are receiving methyldopa and who undergo dialysis may occasionally become hypertensive after the dialysis, since the drug is dialyzable.
McEvoy, G.K. (ed.). American Hospital Formulary Service-Drug Information 19 98. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1998 (Plus Supplements)., p. 1512
Positive direct antiglobulin (Coombs') test results have been reported in about 10-20% of patients receiving methyldopa, usually after 6-12 months of therapy. This phenomenon is dose related, with the lowest incidence in patients receiving 1 g or less of methyldopa daily. In most patients, a postive Coombs' test associated with mehtyldopa therapy is not clinically important. Reversal of the positive Coombs' test occurs within weeks to months after discontinuance of the drug and usually becomes negative within 6 months. Hemolytic anemia has only rarely occurred, although 2 deaths have been reported in patients with methyldopa-induced hemolytic anemia. If anemia or a positive Coombs' test occurs, appropriate laboratory studies should be performed to determine if hemolysis is present; if there is evidence of hemolytic anemia, the drug should be discontinued. Discontinuance of the drug alone or initiation of corticosteroid therapy has produced remission of methyldopa-induced hemolytic anemia.
McEvoy, G.K. (ed.). American Hospital Formulary Service-Drug Information 19 98. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1998 (Plus Supplements)., p. 1511
Nasal congestion occurs commonly in patients receiving methyldopa. Decreased libido and impotence frequently occur in males during therapy with the drug.
McEvoy, G.K. (ed.). American Hospital Formulary Service-Drug Information 19 98. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1998 (Plus Supplements)., p. 1511
For more Drug Warnings (Complete) data for METHYLDOPA (16 total), please visit the HSDB record page.
Methyldopa is indicated for the management of hypertension as monotherapy or in combination with hydrochlorothiazide. Methyldopa injection is used to manage hypertensive crises.
FDA Label
Antihypertensive effects of methyldopa are mostly mediated by its pharmacologically active metabolite, alpha-methylnorepinephrine, which works as an agonist at central inhibitory alpha-adrenergic receptors. Stimulation of alpha-adrenergic receptors leads to decreased peripheral sympathetic tone and reduced arterial pressure. Methyldopa causes a net reduction in the tissue concentration of serotonin, dopamine, norepinephrine, and epinephrine. Overall, meth
